XFRAVSC
Market cap40mUSD
Dec 23, Last price
3.81EUR
1D
-4.99%
1Q
-28.38%
Jan 2017
-67.24%
IPO
-94.45%
Name
4Sc AG
Chart & Performance
Profile
4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs. The company's products in clinical development stage include Resminostat, an orally administered histone deacetylase inhibitor that is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma; and Domatinostat, an orally administered small molecule, which is in Phase Ib/II clinical trial for the treatment of melanoma and Phase II clinical trial for the treatment of gastrointestinal tumor. 4SC AG also out-licenses its products to pharma and biotech companies for the treatment of cancer. The company has a collaboration agreement with the Netherlands Cancer Institute to evaluate Domatinostat in the neoadjuvant setting in melanoma. 4SC AG was founded in 1997 and is headquartered in Planegg, Germany.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | 304 -30.28% | 436 -96.91% | 14,109 526.51% | |||||||
Cost of revenue | 95 | 155 | 383 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 209 | 281 | 13,726 | |||||||
NOPBT Margin | 68.75% | 64.45% | 97.29% | |||||||
Operating Taxes | 15 | 682 | ||||||||
Tax Rate | 7.18% | 242.70% | ||||||||
NOPAT | 194 | (401) | 13,726 | |||||||
Net income | (8,237) -42.64% | (14,361) 49.16% | (9,628) -49.29% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | 3,102 | |||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | (5,219) | (14,825) | (29,022) | |||||||
Cash flow | ||||||||||
Cash from operating activities | (9,548) | (9,383) | (12,069) | |||||||
CAPEX | (2) | (3) | (34) | |||||||
Cash from investing activities | 47 | 104 | (34) | |||||||
Cash from financing activities | 3,000 | |||||||||
FCF | 398 | (173) | 15,340 | |||||||
Balance | ||||||||||
Cash | 8,321 | 14,825 | 29,022 | |||||||
Long term investments | ||||||||||
Excess cash | 8,306 | 14,803 | 28,317 | |||||||
Stockholders' equity | (234,494) | (226,257) | (211,896) | |||||||
Invested Capital | 242,648 | 239,546 | 239,551 | |||||||
ROIC | 0.08% | 6.34% | ||||||||
ROCE | 2.56% | 2.11% | 49.63% | |||||||
EV | ||||||||||
Common stock shares outstanding | 10,114 | 10,113 | 10,135 | |||||||
Price | 8.85 575.57% | 1.31 -62.68% | 3.51 -55.00% | |||||||
Market cap | 89,509 575.61% | 13,249 -62.76% | 35,573 -50.81% | |||||||
EV | 84,290 | (1,576) | 6,551 | |||||||
EBITDA | 740 | 901 | 14,577 | |||||||
EV/EBITDA | 113.91 | 0.45 | ||||||||
Interest | 682 | |||||||||
Interest/NOPBT | 242.70% |